We're excited to have you on board

We'll be sending you the latest buy and sell ratings from Wall Street's top analysts, but first, this... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users: Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users: Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers: Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey.   Matthew Paulson Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.       Today's Exclusive Article Vertical Aerospace Lands $850M Lifeline: What It Means for Investors Author: Jeffrey Neal Johnson. Published: 4/8/2026. Key Points Vertical Aerospace's new long-term financing package provides a clear and durable financial runway for future growth and development. Secured funding allows Vertical Aerospace to accelerate key operational milestones, including final flight tests and public demonstrations. A strong financial position fundamentally improves the investment outlook, shifting focus to technological progress and commercial potential. Special Report: The Biggest IPO Ever: Claim Your Stake Today For months, the narrative around Vertical Aerospace (NYSE: EVTL) centered on a race against time: a shrinking cash balance versus an ambitious, capital-intensive development schedule. That narrative has changed. The electric aircraft developer recently announced an agreement in principle for a comprehensive financing package of up to $850 million — a pivotal moment for the company. Backed by institutional partners Mudrick Capital and Yorkville Advisors, the deal directly addresses the liquidity concerns that had pressured the stock by establishing a multi-year cash runway. Developing and certifying a new aircraft is one of the most demanding industrial undertakings; with its financial footing now steadier, investors can pivot their attention from the balance sheet to operational progress. From Cash Crunch to Capital Runway Altucher: This is My Favorite FREE Starlink Pre-IPO Ticker (Ad) In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… Click here to watch this short 3-minute video now. To appreciate the deal's significance, consider Vertical Aerospace's recent financial position. Vertical Aerospace's fourth-quarter 2025 report painted a challenging picture. The company closed the year with roughly $93 million in cash and cash equivalents and projected a cash burn of $190 million to $200 million over the following 12 months as it ramped up testing and manufacturing activities. That funding gap created substantial uncertainty about the company's ability to continue operating and was a primary reason the stock fell to 52-week lows. The new financing is structured not only to plug the immediate gap but to provide a durable, flexible platform for growth. The agreement delivers an immediate $50 million equity injection, with additional capital expected to follow, strengthening near-term operations. Beyond that initial relief, the package gives Vertical several tools to fund future growth. Key components of this financial toolkit include: Strategic Debt Restructuring: The maturity on existing convertible notes held by Mudrick Capital will be extended from 2028 to 2030. Pushing the repayment deadline two years beyond Vertical's target certification date for the Valo aircraft removes a significant timing risk that could have coincided with the company's most critical operational period. Flexible Growth Capital: The package includes up to $750 million in optional financing through a combination of preferred equity and an equity line of credit. The equity line allows management to raise capital over time by selling shares, a structure intended to be shareholder-friendly by enabling funding at potentially higher valuations as milestones are met. The Next Growth Phase: What the Money Is For With a clearer financial runway, Vertical Aerospace can concentrate on the operational milestones that will unlock value. The funding is intended to accelerate development across all phases, advancing the Valo eVTOL from a promising prototype to a commercially viable aircraft for leading airlines. Investors should now focus on tangible catalysts. The secured capital will support completion of Vertical's piloted transition flight-test program — arguably the most complex aerodynamic phase for an eVTOL, when the aircraft shifts from vertical-rotor thrust to wing-borne forward flight. Successful completion of these tests under the UK Civil Aviation Authority (CAA) would materially de-risk the certification program. The financing also enables high-profile public flight demonstrations, such as at the Farnborough Airshow, and authorizes the start of assembly for the first full-scale Valo certification aircraft, which will incorporate final design updates for regulatory submission. Additionally, it supports expansion of Vertical's in-house battery production. The company's battery-as-a-service model, where airlines replace battery packs annually, is central to its strategy to generate recurring, high-margin revenue beyond aircraft sales. Why the Game Has Officially Changed for Vertical With the immediate financial threat substantially reduced, the investment case for Vertical Aerospace has improved. The market can begin valuing the company more on technological progress and commercial potential than on short-term liquidity concerns. Wall Street analysts currently maintain a consensus Moderate Buy rating on the stock, with an average price target near $11.10. While that outlook depends on continued execution and successful certification, the new financing makes the path to those outcomes more credible. Another notable factor is Vertical Aerospace's high short interest. As of mid-March, more than 25% of publicly available shares were sold short — a substantial bet that the stock would decline, likely driven by concerns about a liquidity crunch. This financing directly challenges that bearish thesis. If Vertical begins delivering on upcoming milestones, short sellers could be pressured to cover positions, potentially triggering a rapid stock rebound independent of longer-term fundamentals. With Financial Risks Grounded, Vertical Looks to the Sky The financing announcement is a transformative catalyst. It provides the capital, time and stability needed to pursue Vertical Aerospace's vision for electric aviation. While significant challenges in aircraft development and regulatory approval remain, the immediate risk of running out of funds has been meaningfully reduced. Vertical now has the resources to advance the Valo program, validate its battery technology and press toward its 2028 certification goal. For investors, the narrative shifts from short-term survival to long-term growth and disruption in the aerospace sector, creating a clearer path for a potential re-rating of the company's stock.

Thank you for subscribing to MarketBeat!   We empower individual investors to make better trading decisions by delivering up-to-the-minute financial information and unbiased investment research.   If you have questions about your newsletter, please don't hesitate to contact MarketBeat's U.S. based support team at contact@marketbeat.com.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2026 MarketBeat Media, LLC. All rights protected. 345 North Reid Place, Suite 620, Sioux Falls, SD 57103. USA..

LIVE in Less than 60 Minutes: Turn Volatility Into Income

New Announcement ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Volatility Is Paying Right Now, We'll Show You How Hey, it's Chris Johnson (CJ) again. There's less than an hour before Karim and I go LIVE for a free strategy session on put selling. 👉The live chat opens at 1:45 PM This market continues to reward disciplined traders who understand how to work with volatility, not fight it. That's exactly what put sellers do. I’m joined by Karim Rahemtulla today on Monument Traders Alliance LIVE to walk through how put selling fits into that framework, where it works, and how to manage risk in real time. If you’ve been looking for a more consistent, premium-driven approach, this is the session to watch. 👉Join the live chat at 1:45 PM I'll see you soon. -CJ Join the Live Chat Monument Traders Alliance, LLC You are receiving this email because you subscribed to Monument Traders Live. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Us | Unsubscribe To cancel by mail or for any other subscription issues, write us at: Monument Traders Live | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website: MonumentTradersAlliance.com © 2026 Monument Traders Alliance, LLC All Rights Reserved     Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.

USAO - Florida, Northern News Update

Offices of the United States Attorneys

You are subscribed to USAO - Florida, Northern news updates. This information has recently been updated, and is now available. Nine Illegal Aliens Convicted of Immigration Offenses in March 04/20/2026 08:00 AM EDT Pensacola and Gainesville – Today, United States Attorney John P. Heekin announced that nine illegal aliens were convicted of federal immigration crimes in the month of March. Fourteen New Indictments Returned for Immigration Offenses in March 04/20/2026 08:00 AM EDT Pensacola and Gainesville – Today, United States Attorney John P. Heekin announced that 14 previously deported illegal aliens have been separately indicted by a federal grand jury for illegal reentry into the United States in the month of March. Havana Man Indicted for Federal Crimes Related to Armed Drug Trafficking 04/20/2026 08:00 AM EDT Tallahassee, Florida – Marlo G. Davis, 47, of Havana, Florida, has been indicted in federal court for possession with intent to distribute cocaine and cocaine base, carrying a firearm during a drug-trafficking crime, and possession of a firearm by a convicted felon.

---

You have received this e-mail because you have asked to be notified of changes to the Offices of the United States Attorneys website. GovDelivery is providing this service on behalf of the Executive Office for United States Attorneys, Department of Justice, 950 Pennsylvania Ave., NW · Washington, DC 20530 · 202-514-2000 and may not use your subscription information for any other purposes.

Manage your Subscriptions | Department of Justice Privacy Policy  | GovDelivery Privacy Policy

Follow the Offices of the United States Attorneys on Twitter: @USAttorneys

🔐 Punch these codes into your ordinary brokerage account

These 18-digit codes have maintained an 84%-win rate, helping users target $6,316 payouts in just 7 days. See how they work. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Editor’s Note: Imagine typing an 18-digit code into your brokerage account and walking away one week later with a $6,316 payday. Sounds like a fantasy, but that’s one of the ways Larry Benedict made over $274 million in profits at his top 1% hedge fund. And now he’s sending the codes to ordinary people. They’ve seen an 84%-win rate so far, and the next code could go out any day now. For details and access, click here or read on… Dear Reader, “Punch this 18-digit code into an ordinary brokerage account,” Larry told me. At first, I was unsure… But Larry Benedict managed one of the top 100 hedge funds in the world, so I paid attention. “If my calculations are correct,” he continued, “this code could put over $6,000 in your account in seven days.” According to Larry, one simple trade could have returned over $6,316 in cold hard cash. And it took just seven days. It was that fast. So what exactly are these codes… and why are they potentially so profitable? He’s just released a new free video explainer. Just click here to see the whole thing (including all of the evidence). Regards, Lauren Wingfield Managing Editor, The Opportunistic Trader Today’s editorial pick for you Boeing’s Q1 Report Confirm It Is Flying Again, But The Cash Register Hasn’t Posted On Apr 22, 2026 by Grayson Cavern There is a version of Boeing Co. (NYSE: BA) in this quarter that looks like a recovery story, and another that looks unfinished. Let’s start with what has clearly improved as revealed in Boeing’s  Q1 2026 earnings release. Revenue rose to $22.2 billion, up 14% year over year, supported by higher aircraft deliveries and strength in defense and services. While earnings per share improved to -$0.11 from -$0.16.  Table of Contents Pay Attention When The Deliveries Begin To Rise Backlog Looks Impressive – But It Isn’t Special The Financial Engine Is Still Lagging The Operational One A Facade For A Bullish Setup The Market Is Waiting For The Last Piece Bullish On The Aerospace Company Although anyone can easily see that Boeing is outperforming, this hasn’t translated into cash just yet. This is a friction in its book, and understanding it could change how you interpret the business beyond headlines. Pay Attention When The Deliveries Begin To Rise The clearest signal of that stabilization is in production and deliveries, not earnings. You see, Boeing delivered exactly 143 aircraft in the quarter, up roughly 10% year over year, with 114 units from the 737 program alone, alongside contributions from the 787, 777, and 767 lines. This matters because delivery volume is the first real indicator that a manufacturing recovery is taking hold. Orders and backlog can sit on paper indefinitely, but deliveries require execution across supply chains, labor, and regulatory compliance. In that sense, Boeing has already crossed a meaningful threshold. Production is also stabilizing. The 737 program is now running at approximately 42 aircraft per month, with plans to move toward 47 per month later in the year, while the 787 program remains steady at around eight per month. These are not peak levels, but they are controlled and trending in the right direction. For a company that spent years struggling to produce consistently, that shift is not only incremental, but it is also, in fact, foundational. Backlog Looks Impressive – But It Isn’t Special It would be easy to anchor the story on backlog, which now stands at approximately $695 billion, including more than 6,100 commercial aircraft. But backlog has never been Boeing’s problem. The company has operated with a massive order book for years, even while destroying value through execution failures and cash burn. I get it, backlog tells you demand exists. Where it fails is when it does not tell you whether that demand can be converted into profitable output. That distinction is critical because it leads directly to the part of the story that remains unresolved. The Financial Engine Is Still Lagging The Operational One Despite higher deliveries and revenue growth, Boeing generated negative free cash flow of $1.5 billion in the quarter, even though operating cash flow improved significantly to -$179 million from -$1.6 billion a year ago. Operating margin also came in at approximately 2.0%, down from 2.4%. Total debt declined to approximately $47.2 billion from $54.1 billion. Sure enough, these are signs of financial progress and recovery. But this recovery breaks down because while the company is producing more aircraft, generating more revenue, and narrowing its losses, it is still not translating that activity into cash generation. Even within the segments, the imbalance is clear. Commercial Airplanes generated $9.2 billion in revenue but remained loss-making, with an operating loss of $563 million, while Global Services delivered $971 million in operating income on $5.4 billion of revenue, highlighting where the company is actually earning money today. In other words, Boeing can deliver planes again and improve its balance sheet, but it still cannot convert those deliveries into cash. A Facade For A Bullish Setup The temptation is to view the cash flow deficit as a reason for caution, and in isolation, it is. But taken in context, it is better understood as a lagging indicator. Operational recovery always precedes financial recovery in manufacturing businesses of this scale. Deliveries improve first, revenue follows, margins expand next, and cash flow comes last. Boeing has already moved through the first two stages and is beginning to work through the third. That sequencing matters because once production stabilizes and margins begin to normalize, the conversion from revenue to cash does not improve gradually – it skyrockets. Fixed costs are absorbed, working capital normalizes, and incremental deliveries carry significantly higher contribution margins. What looks like a cash problem today is, in many ways, the final step in a process that is already well underway. The Market Is Waiting For The Last Piece The market is already starting to price that transition, but it’s still holding back. After bottoming near $189, the stock has reclaimed the $208–$224 range, pushed through short-term resistance, and is now pressing toward $231, with the price reclaiming the 8-, 21-, and 50-day moving averages in sequence. That kind of structure reflects steady accumulation rather than speculative spikes. Volume has also expanded on up-moves, while pullbacks have come on lighter participation, a classic sign that institutions are building positions rather than distributing them. Momentum confirms it. RSI has moved to about 62, not overbought, but firmly in bullish territory, signaling controlled strength rather than exhaustion. The chart is passing the same message along. That is, the market believes the operational recovery is real. What it is still waiting for and what it has not fully priced is the conversion of that recovery into consistent free cash flow. Bullish On The Aerospace Company At this point, the investment case for Boeing is no longer about operational recovery, which is already visible in higher deliveries, stabilizing production, and revenue growth. The only question now is timing: how quickly that progress converts into margins and free cash flow. This is where I lean bullish because what the market is waiting for is not uncertainty but a mechanical outcome. If production holds and volumes scale, fixed costs get absorbed, and cash generation follows. That progression is not optional in a manufacturing recovery; it is inevitable. This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com Your Final Idea: 3 Small-Caps Positioned for What’s Coming Next

We're excited to have you on board

We'll be sending you the latest buy and sell ratings from Wall Street's top analysts, but first, this... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users: Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users: Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers: Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey.   Matthew Paulson Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.       Special Report 3 Ways to Invest in the Growing GLP-1 Weight Loss Market Authored by Nathan Reiff. Published: 4/17/2026. Key Points The GLP-1 agonist market could triple in the coming years, and a number of new players are attempting to gain access to the space with novel drugs in development. Structure Therapeutics may warrant a closer look from investors, as its GLP-1 agonist candidate has shown promising trial results. It's also now possible to gain diversified exposure to the market via ETFs like OZEM and THNR, the former of which in particular has performed well in the last year. Special Report: Elon Musk: This Could Turn $100 into $100,000 Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can gain exposure by targeting companies that manufacture these powerful drugs. It would be a mistake to assume that all GLP-1 sales will be limited to the major products Ozempic and Wegovy, both manufactured by pharma giant Novo Nordisk A/S (NYSE: NVO). Demand in this relatively new space is so large that a growing number of alternatives are emerging despite the apparent dominance of a few major players. Below, we examine a standalone, lesser-known biotech developer with a promising alternative in the pipeline, plus two exchange-traded funds (ETFs) that offer broader, diversified exposure to the industry. A Pivot Toward GLP-1 Drugs Could Be Transformational for Structure Therapeutics The REAL Reason Trump is Invading Iran (Ad) For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is. Structure Therapeutics (NASDAQ: GPCR) is a biotechnology company developing drugs that act on G protein-coupled receptors (GPCRs). The firm has traditionally focused on treatments for metabolic and inflammatory conditions such as fibrosis and nonalcoholic steatohepatitis. The company has recently pivoted toward GLP-1 therapies. Its candidate aleniglipron demonstrated 16.3% weight loss (adjusted for certain trial factors) and could outperform some competitors on safety and manufacturing cost metrics. Although Structure is not currently profitable, it holds a solid cash position of roughly $1.4 billion. That should provide ample runway over the coming quarters as it advances aleniglipron toward a critical Phase 3 trial. Analysts have highlighted Structure's potential based on aleniglipron's results. Of 18 published ratings for GPCR stock, 15 are Buy or equivalent. Shares have been pressured this year, declining about 20% amid challenging external factors, but optimism persists: with a consensus price target of $110, Structure's share price could more than double from current levels. The First GLP-1 Agonist ETF Is Building a Track Record of Success There is significant opportunity in the GLP-1 space, and a recent wave of ETFs has emerged to capture that growth. The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) was an early entrant, launching in mid-2024. The fund takes a focused approach, targeting roughly two dozen pharmaceutical companies positioned to benefit from the expansion of the GLP-1 agonist industry. Novo Nordisk and major rival Eli Lilly & Co. (NYSE: LLY) feature prominently, together accounting for nearly 30% of the portfolio. The basket also includes a mix of domestic and international names to provide geographic diversification. Importantly, OZEM provides exposure not only to large companies producing or selling GLP-1 therapeutics, but also to firms developing complementary weight-loss technologies and companies that support the supply chain for production. As an actively managed fund, OZEM carries an expense ratio of 0.59%. That is higher than many passive ETFs but competitive relative to other active strategies. The fund is niche, with a modest asset base of about $52 million and relatively low trading volumes. Still, it has risen roughly 45% over the past year, rewarding investors who bought and held. A modest dividend is an added benefit. Another GLP-1 ETF With a Passive Approach Another option in the GLP-1 ETF space is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR). In many respects THNR resembles OZEM: it also charges a 0.59% annual fee and holds roughly two dozen pharmaceutical names connected to the GLP-1 market. It includes heavy positions in Novo Nordisk and Eli Lilly, though those two companies together make up only about a quarter of the portfolio, leaving additional room for other exposures. A key difference is that THNR is passively managed. It tracks an index of companies in the GLP-1 sector, with weightings determined by float-adjusted market capitalization and influenced by trading volume. The index is rebalanced quarterly, and some investors may prefer this passive, market-reflective approach over active management. THNR's asset base is small—about $4 million—and trading volume is light. The fund has returned roughly 30% over the last year, which is solid but notably below OZEM's performance.

Thank you for subscribing to MarketBeat!   MarketBeat empowers individual investors to make better trading decisions by offering real-time financial information and unbiased investment analysis.   If you need assistance with your subscription, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2026 MarketBeat Media, LLC. All rights reserved. 345 N Reid Pl. #620, Sioux Falls, S.D. 57103. U.S.A..